Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease

Anavex Life Sciences recently announced that its clinical trial application for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority.

Read more »

The Neurology Market: A Glance (video)

The plethora of recent reports of new genes and pathways linked to neurological diseases shows that the underlying causes of these diseases are far from certain.

Read more »